{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:32:12Z","timestamp":1788492732751,"version":"build-2803163510"},"reference-count":92,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203814"],"award-info":[{"award-number":["82203814"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82371795"],"award-info":[{"award-number":["82371795"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2022CFB241"],"award-info":[{"award-number":["2022CFB241"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Natural Science Foundation of Hubei Province","doi-asserted-by":"publisher","award":["2024BCB047"],"award-info":[{"award-number":["2024BCB047"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Programmed cell death protein 1 (PD-1) and its ligand, programmed death-ligand 1 (PD-L1), are vital molecules in immune checkpoints, significantly impacting cancer treatment. Recent studies have increasingly highlighted the complex roles of the PD-1\/PD-L1 pathway in cardiovascular diseases, particularly in myocardial infarction (MI). In addition to being involved in immune modulation and the inflammatory response post-myocardial ischemia, this pathway is also crucial for myocardial repair and regeneration. Additionally, the clinical application of PD-1\/PD-L1 immune checkpoint inhibitors has led to groundbreaking advances in cancer treatment; however, concerns regarding cardiotoxicity and myocardial injury as adverse events have also been raised. This review systematically examines the pathophysiological mechanisms of the PD-1\/PD-L1 pathway in myocardial infarction, explores its potential as a therapeutic target, and assesses the adverse cardiovascular reactions associated with existing immune checkpoint inhibitors and management strategies. The aim of this study was to provide a theoretical basis and clinical guidance for future immunotherapeutic approaches for treating myocardial infarction.<\/jats:p>","DOI":"10.3389\/fcvm.2025.1691863","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:33:41Z","timestamp":1764138821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The role of the PD-1\/PD-L1 immune checkpoint pathway in myocardial infarction: a review from pathophysiological mechanisms to therapeutic strategies"],"prefix":"10.3389","volume":"12","author":[{"given":"Zilong","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjie","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinyan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","article-title":"The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers","volume":"13","author":"Tang","year":"2022","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.3390\/ijms25052502","article-title":"Association between immune checkpoint inhibitors and atherosclerotic cardiovascular disease risk: another brick in the wall","volume":"25","author":"Piras","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1077290","DOI":"10.3389\/fcvm.2022.1077290","article-title":"Cardiac repair after myocardial infarction: a two-sided role of inflammation-mediated","volume":"9","author":"Li","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/s41420-022-01235-7","article-title":"Inflammation in myocardial infarction: roles of mesenchymal stem cells and their secretome","volume":"8","author":"Shao","year":"2022","journal-title":"Cell Death Discov"},{"key":"B5","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1093\/jjco\/hyac041","article-title":"Atherosclerotic cardiovascular events associated with immune checkpoint inhibitors in cancer patients","volume":"52","author":"Tajiri","year":"2022","journal-title":"Jpn J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11239-025-03081-7","article-title":"Immune checkpoint inhibitors and myocardial infarction","volume":"58","author":"Juhasz","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/PAI.0000000000000712","article-title":"PD-L1 copy number variation does not correlate with PD-L1 expression or response to anti-PD-1 immunotherapy in patients with advanced melanomas","volume":"28","author":"P\u00e9rottet","year":"2020","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/biomedicines9111702","article-title":"Posttranslational modifications in PD-L1 turnover and function: from cradle to grave","volume":"9","author":"Yu","year":"2021","journal-title":"Biomedicines"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/liv.15666","article-title":"Expression pattern of PD-1\/PD-L1 in primary liver cancer with clinical correlation","volume":"43","author":"Zeng","year":"2023","journal-title":"Liver Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e67726","DOI":"10.7759\/cureus.67726","article-title":"Evidence of programmed death-ligand 1 expression in a highly inflammatory prostate: a literature review and our experience","volume":"16","author":"Koleva","year":"2024","journal-title":"Cureus"},{"key":"B11","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/cbf.3827","article-title":"Structure of PD1 and its mechanism in the treatment of autoimmune diseases","volume":"41","author":"Rezayi","year":"2023","journal-title":"Cell Biochem Funct"},{"key":"B12","doi-asserted-by":"publisher","first-page":"7533","DOI":"10.3390\/ijms23147533","article-title":"PD1 Deficiency modifies cardiac immunity during baseline conditions and in reperfused acute myocardial infarction","volume":"23","author":"Michel","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1007\/s12094-024-03835-4","article-title":"Progress in understanding the regulatory mechanisms of immune checkpoint proteins PD-1 and PD-L1 expression","volume":"27","author":"Wu","year":"2025","journal-title":"Clin Transl Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1038\/s41590-021-01060-7","article-title":"Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection","volume":"22","author":"Snell","year":"2021","journal-title":"Nat Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1111\/cbdd.13677","article-title":"Programmed cell death ligand-1: a dynamic immune checkpoint in cancer therapy","volume":"95","author":"Kalim","year":"2020","journal-title":"Chem Biol Drug Des"},{"key":"B16","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41590-020-0620-x","article-title":"PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer","volume":"21","author":"Diskin","year":"2020","journal-title":"Nat Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"794226","DOI":"10.3389\/fimmu.2021.794226","article-title":"pH low insertion peptide-modified programmed cell death-ligand 1 potently suppresses T-cell activation under acidic condition","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e2412340","DOI":"10.1002\/adma.202412340","article-title":"Reversing immune checkpoint inhibitor-associated cardiotoxicity via bioorthogonal metabolic engineering-driven extracellular vesicle redirecting","volume":"36","author":"Fan","year":"2024","journal-title":"Adv Mater"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12863-022-01081-7","article-title":"Bioinformatic analysis of PD-1 checkpoint blockade response in influenza infection","volume":"23","author":"Ou","year":"2022","journal-title":"BMC Genom Data"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e009475","DOI":"10.1136\/jitc-2024-009475","article-title":"Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1\/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab","volume":"12","author":"Cavalcante","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"153609","DOI":"10.1016\/j.prp.2021.153609","article-title":"Autophagy in cardiac myxoma: an important puzzle piece in understanding its inflammatory environment","volume":"226","author":"Sramek","year":"2021","journal-title":"Pathol Res Pract"},{"key":"B22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.alit.2022.06.006","article-title":"Chronopharmacology of immune-related diseases","volume":"71","author":"Ohdo","year":"2022","journal-title":"Allergol Int"},{"key":"B23","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3892\/br.2023.1637","article-title":"Recruitment of myeloid-derived suppressor cells and regulatory T-cells is associated with the occurrence of acute myocardial infarction","volume":"19","author":"Zhang","year":"2023","journal-title":"Biomed Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"759972","DOI":"10.3389\/fcvm.2021.759972","article-title":"Myocardial PD-L1 expression in patients with ischemic and non-ischemic heart failure","volume":"8","author":"Kushnareva","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1038\/s41598-024-85065-w","article-title":"PD-L1 monoclonal antibody alleviated MI injury of left ventricular function via modulating CD47\/SHP2\/SIRP\u03b1\/SYK\/Fc\u03b3R signalings in tumor associated macrophages","volume":"15","author":"Kong","year":"2025","journal-title":"Sci Rep"},{"key":"B26","doi-asserted-by":"publisher","first-page":"113607","DOI":"10.1016\/j.jconrel.2025.113607","article-title":"Multifunctional nanoparticles for immune regulation and oxidative stress alleviation in myocarditis","volume":"381","author":"Ye","year":"2025","journal-title":"J Control Release"},{"key":"B27","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s44161-024-00447-7","article-title":"The PD-1-PD-L1 pathway maintains an immunosuppressive environment essential for neonatal heart regeneration","volume":"3","author":"Vargas Aguilar","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40959-021-00128-5","article-title":"Adverse cardiovascular complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched cohort study with competing risk analysis","volume":"8","author":"Zhou","year":"2022","journal-title":"Cardiooncology"},{"key":"B29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/COC.0000000000001166","article-title":"Cardiovascular risk profile of nivolumab anti-cancer therapy: a review of current literature","volume":"48","author":"Qureshi","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"119219","DOI":"10.1016\/j.atherosclerosis.2025.119219","article-title":"Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies","volume":"405","author":"Strijdhorst","year":"2025","journal-title":"Atherosclerosis"},{"key":"B31","doi-asserted-by":"publisher","first-page":"584626","DOI":"10.3389\/fimmu.2020.584626","article-title":"Regulation of PD-L1 expression by NF-\u03baB in cancer","volume":"11","author":"Antonangeli","year":"2020","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"13422","DOI":"10.1038\/s41598-025-98135-4","article-title":"Improved acid-driven inhibition of effector T cell function by a pHLIP variant-conjugated PD-L1","volume":"15","author":"Zheng","year":"2025","journal-title":"Sci Rep"},{"key":"B33","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1158\/2767-9764.CRC-24-0125","article-title":"A checkpoint reversal receptor mediates bipartite activation and enhances CAR T-cell function","volume":"5","author":"Landi","year":"2025","journal-title":"Cancer Res Commun"},{"key":"B34","doi-asserted-by":"publisher","first-page":"858379","DOI":"10.3389\/fonc.2022.858379","article-title":"PD-L1 Mediates IFN\u03b3-regulation of glucose but not of tryptophan metabolism in clear cell renal cell carcinoma","volume":"12","author":"Garige","year":"2022","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1424770","DOI":"10.3389\/fcvm.2024.1424770","article-title":"PD-1\/PD-L1 and coronary heart disease: a Mendelian randomization study","volume":"11","author":"Zeng","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B36","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1161\/CIRCULATIONAHA.107.709360","article-title":"Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart","volume":"116","author":"Grabie","year":"2007","journal-title":"Circulation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.jsps.2022.06.010","article-title":"Immune checkpoint inhibitors and potential risk of thromboembolic events: analysis of the WHO global database of individual case safety reports","volume":"30","author":"Alghamdi","year":"2022","journal-title":"Saudi Pharm J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1016\/j.jaccao.2022.11.008","article-title":"Pre-Existing autoimmune disease increases the risk of cardiovascular and noncardiovascular events after immunotherapy","volume":"4","author":"Lee","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e16373","DOI":"10.1016\/j.heliyon.2023.e16373","article-title":"Cardiovascular events after the initiation of immune checkpoint inhibitors","volume":"9","author":"Suzuki","year":"2023","journal-title":"Heliyon"},{"key":"B40","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4330\/wjc.v12.i11.584","article-title":"Cardiac adverse events of immune checkpoint inhibitors in oncology patients: a systematic review and meta-analysis","volume":"12","author":"Nso","year":"2020","journal-title":"World J Cardiol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"S1875-2136(25)00402-4","DOI":"10.1016\/j.acvd.2025.06.073","article-title":"Cardiovascular safety of a standardized outpatient triage and diagnostic approach for suspected cardiovascular immune-related adverse events of immune checkpoint inhibitors","volume":"118","author":"Cribari","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"645245","DOI":"10.3389\/fonc.2021.645245","article-title":"Risk of cardiac adverse events in patients treated with immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"11","author":"Hu","year":"2021","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/cancers17050827","article-title":"Characterizing cardiotoxicity of FDA-approved soft tissue sarcoma targeted therapies and immune checkpoint inhibitors: a systematic review","volume":"17","author":"Houmsse","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"e87049","DOI":"10.7759\/cureus.87049","article-title":"Cardiovascular toxicity associated with immune checkpoint inhibitors: interpreting the discrepancy between clinical trials and real-world data","volume":"17","author":"Papanikolopoulou","year":"2025","journal-title":"Cureus"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1340373","DOI":"10.3389\/fimmu.2024.1340373","article-title":"Immune checkpoint inhibitors associated cardiovascular immune-related adverse events","volume":"15","author":"Jo","year":"2024","journal-title":"Front Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s10140-020-01765-6","article-title":"Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients","volume":"27","author":"Ansari-Gilani","year":"2020","journal-title":"Emerg Radiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s11886-023-01915-5","article-title":"Role of biomarkers in the management of immune-checkpoint inhibitor-related myocarditis","volume":"25","author":"Vasbinder","year":"2023","journal-title":"Curr Cardiol Rep"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e260349","DOI":"10.1136\/bcr-2024-260349","article-title":"Triple M overlap syndrome following pembrolizumab treatment: importance of multidisciplinary approach","volume":"18","author":"G\u00f3mez","year":"2025","journal-title":"BMJ Case Rep"},{"key":"B49","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12890-023-02417-4","article-title":"A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer","volume":"23","author":"Hu","year":"2023","journal-title":"BMC Pulm Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejca.2022.07.018","article-title":"Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: report from an international registry","volume":"177","author":"Nowatzke","year":"2022","journal-title":"Eur J Cancer"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1559173","DOI":"10.3389\/fcvm.2025.1559173","article-title":"Severe immune-mediated myocarditis caused by sintilimab combined with gemcitabine: a case report and literature review","volume":"12","author":"Yang","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e70131","DOI":"10.1111\/echo.70131","article-title":"Cardiac magnetic resonance imaging in immune checkpoint inhibitor-related myocarditis","volume":"42","author":"Hammer","year":"2025","journal-title":"Echocardiography"},{"key":"B53","doi-asserted-by":"publisher","first-page":"e80732","DOI":"10.7759\/cureus.80732","article-title":"A case of nivolumab-induced multiorgan toxicity: concurrent myocarditis and interstitial pneumonia","volume":"17","author":"Fukushima","year":"2025","journal-title":"Cureus"},{"key":"B54","doi-asserted-by":"publisher","first-page":"e001719","DOI":"10.1136\/jitc-2020-001719","article-title":"Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival","volume":"9","author":"Sussman","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B55","doi-asserted-by":"publisher","first-page":"101220","DOI":"10.1016\/j.blre.2024.101220","article-title":"Thrombotic events associated with immune checkpoint inhibitors and novel antithrombotic strategies to mitigate bleeding risk","volume":"67","author":"Chen","year":"2024","journal-title":"Blood Rev"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e0321112","DOI":"10.1371\/journal.pone.0321112","article-title":"Venous and arterial thrombosis in patients receiving immune checkpoint inhibitors","volume":"20","author":"Lent","year":"2025","journal-title":"PLoS One"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2921","DOI":"10.1111\/jth.15883","article-title":"The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: a Danish cohort study","volume":"20","author":"Overvad","year":"2022","journal-title":"J Thromb Haemost"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.3390\/biomedicines12081927","article-title":"Combination of anti-CD40 and anti-CD40L antibodies as co-stimulation blockade in preclinical cardiac xenotransplantation","volume":"12","author":"Bender","year":"2024","journal-title":"Biomedicines"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1093\/eurheartjsupp\/suaf083.219","article-title":"Myocardial expression of immune checkpoint molecules in patients with advanced heart failure","volume":"27","author":"Gergely","year":"2025","journal-title":"Eur Heart J Suppl"},{"key":"B60","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/1750743X.2025.2501922","article-title":"Validating Khorana risk score in gastric cancer patients on immune checkpoint inhibitors and chemotherapy","volume":"17","author":"Song","year":"2025","journal-title":"Immunotherapy"},{"key":"B61","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.3390\/jcm13133773","article-title":"Venous and arterial thromboembolism in lung cancer patients: a retrospective analysis","volume":"13","author":"Morath","year":"2024","journal-title":"J Clin Med"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/jcpe.13853","article-title":"Treated periodontitis and recurrent events after first-time myocardial infarction: a Danish nationwide cohort study","volume":"50","author":"Wagner","year":"2023","journal-title":"J Clin Periodontol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/ijms25010134","article-title":"PD-L1 and AKT overexpressing adipose-derived mesenchymal stem cells enhance myocardial protection by upregulating CD25+ T cells in acute myocardial infarction rat model","volume":"25","author":"Lin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12964-025-02073-7","article-title":"A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling","volume":"23","author":"Ferrara","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B65","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/cvr\/cvaa028","article-title":"Extracellular vesicles from human cardiovascular progenitors trigger a reparative immune response in infarcted hearts","volume":"117","author":"Lima Correa","year":"2021","journal-title":"Cardiovasc Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.1038\/s41467-023-40186-0","article-title":"Ezh2 emerges as an epigenetic checkpoint regulator during monocyte differentiation limiting cardiac dysfunction post-MI","volume":"14","author":"Rondeaux","year":"2023","journal-title":"Nat Commun"},{"key":"B67","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s44161-024-00461-9","article-title":"PD-1-PD-L1 immunomodulatory pathway regulates cardiac regeneration","volume":"3","author":"Qin","year":"2024","journal-title":"Nat Cardiovasc Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13071-025-06854-4","article-title":"PD-1-dependent therapeutic effect of Trichinella spiralis cystatin on myocardial infarction in a mice model","volume":"18","author":"Zhang","year":"2025","journal-title":"Parasit Vectors"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1467095","DOI":"10.3389\/fimmu.2024.1467095","article-title":"Thymic stromal lymphopoietin modulates T cell response and improves cardiac repair post-myocardial infarction","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1139\/bcb-2025-0170","article-title":"Identification of features and differences in PD-1 inhibitor-associated myocarditis and acute myocardial infarction using proteomic analysis: a clinical and preclinical study","volume":"103","author":"Luo","year":"2025","journal-title":"Biochem Cell Biol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1161\/CIRCRESAHA.124.324260","article-title":"Visualizing immune checkpoint inhibitors derived inflammation in atherosclerosis","volume":"135","author":"Lou","year":"2024","journal-title":"Circ Res"},{"key":"B72","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10565-020-09530-8","article-title":"Human umbilical cord blood-derived MSCs exosome attenuate myocardial injury by inhibiting ferroptosis in acute myocardial infarction mice","volume":"37","author":"Song","year":"2021","journal-title":"Cell Biol Toxicol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"652186","DOI":"10.3389\/fcvm.2021.652186","article-title":"Immune checkpoint inhibitors and atherosclerotic vascular events in cancer patients","volume":"8","author":"Inno","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1117362","DOI":"10.3389\/fcvm.2023.1117362","article-title":"Predictive value of atherogenic index of plasma and atherogenic index of plasma combined with low-density lipoprotein cholesterol for the risk of acute myocardial infarction","volume":"10","author":"Chen","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"e60087","DOI":"10.7759\/cureus.60087","article-title":"Myocardial bridging in patients undergoing coronary angiography for coronary artery disease","volume":"16","author":"Mishra","year":"2024","journal-title":"Cureus"},{"key":"B76","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.acvd.2020.04.007","article-title":"Colchicine and myocardial infarction: a review","volume":"113","author":"Akodad","year":"2020","journal-title":"Arch Cardiovasc Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1177\/00033197221089373","article-title":"Assessment of a new electrocardiographic marker for the diagnosis of myocardial infarction with non-obstructive coronary arteries","volume":"74","author":"Demirelli","year":"2023","journal-title":"Angiology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"ytae429","DOI":"10.1093\/ehjcr\/ytae429","article-title":"Case report of an ST-elevation myocardial infarction-like presentation of an immune checkpoint (PD-1\/PD-L1) inhibitor-associated myocarditis","volume":"8","author":"Declercq","year":"2024","journal-title":"Eur Heart J Case Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1455347","DOI":"10.3389\/fimmu.2025.1455347","article-title":"Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review","volume":"16","author":"Man","year":"2025","journal-title":"Front Immunol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s00262-024-03899-9","article-title":"Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study","volume":"74","author":"Chen","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"B81","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41420-024-02064-6","article-title":"The roles of Th cells in myocardial infarction","volume":"10","author":"Liu","year":"2024","journal-title":"Cell Death Discov"},{"key":"B82","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1148\/radiol.2021210814","article-title":"Cardiac MRI depicts immune checkpoint inhibitor-induced myocarditis: a prospective study","volume":"301","author":"Faron","year":"2021","journal-title":"Radiology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.3390\/ijms26031238","article-title":"Glycoscience in advancing PD-1\/PD-L1-axis-targeted tumor immunotherapy","volume":"26","author":"Sun","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.hrtlng.2024.04.018","article-title":"Causal role of circulating inflammatory cytokines in cardiac diseases, structure and function","volume":"67","author":"Ruan","year":"2024","journal-title":"Heart Lung"},{"key":"B85","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12935-024-03293-6","article-title":"MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1\/PD-L1 and CTLA-4 pathways","volume":"24","author":"Zabeti Touchaei","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B86","doi-asserted-by":"publisher","first-page":"3884","DOI":"10.1038\/s41467-024-48200-9","article-title":"PD-1\/CD80+ small extracellular vesicles from immunocytes induce cold tumours featured with enhanced adaptive immunosuppression","volume":"15","author":"Zhang","year":"2024","journal-title":"Nat Commun"},{"key":"B87","doi-asserted-by":"publisher","first-page":"350","DOI":"10.14735\/amko2020350","article-title":"Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors","volume":"33","author":"Mladosievi\u010dov\u00e1","year":"2020","journal-title":"Klin Onkol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.2147\/DDDT.S486816","article-title":"Targeting macrophage phenotype for treating heart failure: a new approach","volume":"18","author":"Shi","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"B89","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s00520-024-08344-2","article-title":"The cardiac-related adverse events of PD-1\/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis","volume":"32","author":"Chen","year":"2024","journal-title":"Support Care Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"779691","DOI":"10.3389\/fimmu.2022.779691","article-title":"Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors","volume":"13","author":"Chennamadhavuni","year":"2022","journal-title":"Front Immunol"},{"key":"B91","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/anae.16493","article-title":"Cardiotoxicity and peri-operative considerations in immune checkpoint inhibitor and chimeric antigen receptor T-cell therapy: a narrative review","volume":"80","author":"Malode","year":"2025","journal-title":"Anaesthesia"},{"key":"B92","doi-asserted-by":"publisher","first-page":"355","DOI":"10.5551\/jat.64183","article-title":"Prognostic significance of soluble PD-L1 on cardiovascular outcomes in patients with coronary artery disease","volume":"31","author":"Miyazaki","year":"2024","journal-title":"J Atheroscler Thromb"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1691863\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T06:33:42Z","timestamp":1764138822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1691863\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":92,"alternative-id":["10.3389\/fcvm.2025.1691863"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1691863","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"article-number":"1691863"}}